Visión generalGráficoPerfilEstadísticas claveBalance generalNoticias
Derivados
TraderScreen

IPSEN S.A. PORT. EO 1/  FR0010259150  /

Lang & Schwarz
21/12/2024  13:03:44 Diferencia 0.00 Volumen Bid13:03:44 Ask13:03:44 Capitalización de mecado Dividendo A. P/E Ratio
107.80EUR 0.00% -
Volumen de negocios: -		 107.80Volumen de oferta: - 108.00Tamaño/ Volumen/ Formato de Ask: - 9.05 mil millonesEUR 1.11% 13.86
GlobeNewswire 26/07 Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and K...
GlobeNewswire 25/07 Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its ful...
GlobeNewswire 25/07 Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for ...
GlobeNewswire 11/07 Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug con...
GlobeNewswire 02/07 Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroend...
GlobeNewswire 10/06 Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primar...
GlobeNewswire 07/06 Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell eng...
GlobeNewswire 06/06 Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   
GlobeNewswire 05/06 Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with...
GlobeNewswire 02/05 Ipsen appoints Keira Driansky as EVP, President of North America
GlobeNewswire 24/04 Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines...
GlobeNewswire 22/04 Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological di...
GlobeNewswire 02/04 Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid t...
GlobeNewswire 13/02 Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreat...
GlobeNewswire 08/02 Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
GlobeNewswire 07/12/2023 Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the trea...
GlobeNewswire 07/12/2023 Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid...
GlobeNewswire 13/11/2023 Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaki...
GlobeNewswire 26/10/2023 Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidan...
GlobeNewswire 23/10/2023 Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
GlobeNewswire 03/10/2023 Ipsen updates on QM-1114 regulatory process
GlobeNewswire 04/09/2023 Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
GlobeNewswire 01/09/2023 Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
GlobeNewswire 21/08/2023 Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Caboza...
GlobeNewswire 16/08/2023 US FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people w...